| Literature DB >> 34687563 |
M da Costa Lima1, M Magnani2, M Dos Santos Lima3, C P de Sousa4, J D Dubreuil5, E L de Souza1.
Abstract
This study aimed to evaluate the inhibitory effects of phenolic-rich extracts from acerola (Malpighia emarginata D.C., PEA), cashew apple (Anacardium occidentale L., PEC) and mango (Mangifera indica L., PEM) by-products on distinct enterotoxigenic Escherichia coli (ETEC) strains. The capability of PEA and PEC of impairing various physiological functions of ETEC strains was investigated with multiparametric flow cytometry. Procyanidin B2 , myricetin and p-coumaric acid were the major phenolic compounds in PEA, PEC and PEM, respectively. PEA and PEC had lower minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) (MIC: 31·25 mg ml-1 ; MBC: 62·5 mg ml-1 ) on ETEC strains than PEM (MIC and MIC: >1000 mg ml-1 ). PEA and PEC (15·6, 31·2, 62·5 mg ml-1 ) caused viable count reductions (P < 0·05) on ETEC strains after 24 h of exposure, notably the ≥3 log reductions caused by 62·5 mg ml-1 . The 24 h exposure of ETEC strains to PEA and PEC (31·2, 62·5 mg ml-1 ) led to high sizes of cell subpopulations with concomitant impairments in cell membrane polarization and permeability, as well as in enzymatic, respiratory and efflux activities. PEA and PEC are effective in inhibiting ETEC through a multi-target action mode with disturbance in different physiological functions.Entities:
Keywords: antibacterial properties; cell damage; enterotoxigenic Escherichia coli; extracts; fruit
Mesh:
Substances:
Year: 2021 PMID: 34687563 PMCID: PMC9539876 DOI: 10.1111/lam.13586
Source DB: PubMed Journal: Lett Appl Microbiol ISSN: 0266-8254 Impact factor: 2.813
Phenolic compounds identified (average ± standard deviation) in phenolic‐rich extracts from acerola (PEA), cashew apple (PEC) and mango (PEM) by‐products
| Phenolic compounds | PEA (mg 100 g−1) | PEC (mg 100 g−1) | PEM (mg 100 g−1) |
|---|---|---|---|
| Anthocyanidins | |||
| Cyanidin 3,5‐diglucoside | 0·7 (±0·2) | <LOD | <LOD |
| Malvidin 3,5‐diglucoside | <LOD | <LOD | 0·9 (±0·2) |
| Malvidin 3‐glucoside | 8·9 (±0·9) | <LOD | <LOD |
| Pelargonidin 3‐glucoside | 1·3 (±0·3)a | 2·4 (±0·1)b | <LOD |
| Pelargonidin 3,5‐diglucoside | <LOD | <LOD | 1·3 (±0·0) |
| Petunidin 3‐glucoside | 14·7 (±1·7) | <LOD | <LOD |
| Flavanols | |||
| Catechin | 35·1 (±0·4)a | 10·5 (±0·2)b | 2·7 (±0·2)c |
| Epicatechin | <LOD | <LOD | 1·3 (±0·1) |
| Epicatechin gallate | <LOD | <LOD | 0·7 (±0·3) |
| Epigallocatechin gallate | 3·8 (±1·0)a | <LOD | 2·4 (±0·1)b |
| Procyanidin A2 | 3·8 (±0·0)a | <LOD | 0·9 (±0·2)b |
| Procyanidin B1 | 20·9 (±0·3)a | 0·3 (±0·1)c | 15·9 (±2·3)b |
| Procyanidin B2 | 39·1 (±0·7)a | 17·5 (±0·5)b | 9·0 (±0·3)c |
| Flavonol | |||
| Kampferol 3‐glucoside | 12·0 (±0·2)a | 0·4 (±0·0)b | 0·7 (±0·1)b |
| Myricetin | <LOD | 52·0 (±0·4)a | 0·6 (±0·2)b |
| Quercetin 3‐glucoside | 15·8 (±0·1)b | 3·2 (±0·0)c | 18·1 (±0·9)a |
| Rutin | 1·2 (±0·0)b | 2·8 (±0·0)b | 6·9 (±0·8)a |
| Flavanones | |||
| Hesperetin | 32·6 (±0·6)a | 3·5 (±0·0)b | 34·8 (±1·7)a |
| Naringenin | 16·7 (±0·3)a | <LOD | 1·1 (±0·2)b |
| Hydroxybenzoic acids | |||
| Gallic acid | <LOD | <LOD | 0·2 (±0·0) |
| Syringic acid | <LOD | <LOD | 1·6 (±0·2) |
| Hydroxycinnamic acids | |||
| Caffeic acid | 0·9 (±0·1)a | < LOD | 1·3 (±0·3)a |
| Caftaric acid | 19·4 (±3·6)a | 0·3 (±0·1)b | 3·6 (±0·4)b |
| Chlorogenic acid | 6·5 (±1·1)a | <LOD | 1·4 (±0·2)b |
|
| <LOD | <LOD | 34·9 (±5·6) |
| Stilbenes | |||
|
| 2·5 (±0·2)b | <LOD | 14·3 (±2·7)a |
|
| 8·1 (±0·2)a | <LOD | 3·0 (±0·2)b |
| Sum of contents of determined phenolic compounds | 244·0 | 93·0 | 157·3 |
Different letters in the same row denote significant differences (P < 0·05), based on Kruskal–Wallis or Mann–Whitney U test.
Gallic acid (limit of detection (LOD) 0·001 mg 100 g−1 and limit of quantification (LOQ) 0·001 mg 100 g−1), syringic acid (LOD 0·008 mg 100 g−1 and LOQ 0·012 mg 100 g−1), cis‐resveratrol (LOD 0·008 mg 100 g−1 and LOQ 0·010 mg 100 g−1), hesperidin (LOD 0·012 mg 100 g−1 and LOQ 0·017 mg 100 g−1), naringenin (LOD 0·016 mg 100 g−1 and LOQ 0·022 mg 100 g−1), epicatechin (LOD 0·006 mg 100 g−1 and LOQ 0·007 mg 100 g−1), catechin (LOD 0·006 mg 100 g−1 and LOQ 0·008 mg 100 g−1), epicatechin‐gallate (LOD 0·006 mg 100 g−1 and LOQ 0·007 mg 100 g−1), epigallocatechin‐gallate (LOD 0·004 mg 100 g−1 and LOQ 0·005 mg 100 g−1), procyanidin A2 (LOD 0·006 mg 100 g−1 and LOQ 0·007 100 g−1), procyanidin B1 (LOD 0·001 mg 100 g−1 and LOQ 0·001 mg 100 g−1) and procyanidin B2 (LOD 0·004 mg 100 g−1 and LOQ 0·006 mg 100 g−1), trans‐caftaric acid (LOD 0·009 mg 100 g−1 and LOQ 0·001 100 g−1), ρ‐coumaric acid (LOD 0·010 mg 100 g−1 and LOQ 0·012 mg 100 g−1), chlorogenic acid (LOD 0·011 mg 100 g−1 and LOQ 0·015 mg 100 g−1), caffeic acid (LOD 0·001 mg 100 g−1 and LOQ 0·001 mg 100 g−1), trans‐resveratrol (LOD 0·004 mg 100 g−1 and LOQ 0·006 mg 100 g−1), kaempferol (LOD 0·010 mg 100 g−1 and LOQ 0·012 mg 100 g−1), quercetin 3‐glucoside (LOD 0·011 mg 100 g−1 and LOQ 0·014 mg 100 g−1), rutin (LOD 0·008 mg 100 g−1 and LOQ 0·010 mg 100 g−1), myricetin (LOD 0·005 mg 100 g−1 and LOQ 0·007 mg g−1), malvidin 3‐glucoside (LOD 0·085 mg 100 g−1 and LOQ 0·141 mg 100 g−1), cyanidin 3‐glucoside (LOD 0·011 mg 100 g−1 and LOQ 0·015 mg 100 g−1), malvidin 3,5‐diglucoside (LOD 0·024 mg 100 g−1 and LOQ 0·028 mg 100 g−1), cyanidin 3,5‐diglucoside (LOD 0·007 mg 100 g−1 and LOQ 0·008 mg 100 g−1), pelargonidin 3‐glucoside (LOD 0·006 mg 100 g−1 and LOQ 0·008 mg 100 g−1), delphinidin 3‐glucoside (LOD 0·017 mg 100 g−1 and LOQ 0·022 mg 100 g−1), pelargonidin 3,5‐diglucoside (LOD 0·005 mg 100 g−1 and LOQ 0·005 mg 100 g−1), petunidin 3‐glucoside (LOD 0·010 mg 100 g−1 and LOQ 0·012 mg 100 g−1).
Figure 1Viable counts of enterotoxigenic Escherichia coli ECL 19790 (a), ECL 20440 (b), ECL 23141 (c), ECL 20898 (d) and ECL 21858 (e) as a function of the exposure to different concentrations of phenolic‐rich extract from acerola by‐products (PEA). 62·5 mg ml−1 (), 31·2 mg ml−1 (), 15·6 mg ml−1 (), control (without exposure to extract) ().
Figure 2Viable counts of enterotoxigenic Escherichia coli ECL 19790 (a), ECL 20440 (b), ECL 23141 (c), ECL 20898 (d) and ECL 21858 (e) as a function of the exposure to phenolic‐rich extract from cashew apple by‐products (PEC) in concentrations of 62·5 mg ml−1 (), 31·2 mg ml−1 (), 15·6 mg ml−1 (), control (without exposure to extract) ().
Size of subpopulations (average ± standard deviation) of enterotoxigenic Escherichia coli strains (ECL 20440, ECL 23141 and ECL 21858) stained with PI, BOX, cFDA, CTC and EB after exposure to two different concentrations of phenolic‐rich extract from acerola by‐products (PEA, 31·25 and 62·50 mg ml−1)
| Cellular structure or function disruption | Enterotoxigenic | Treatments | ||
|---|---|---|---|---|
| Control (without exposure to extract) | PEA (31·25 mg ml−1) | PEA (62·50 mg ml−1) | ||
| Size of subpopulations (%) | ||||
| Permeabilized cells (PI+) | ECL 20440 | 5·6 ± 0.2Ac | 11·5 ± 2.7Bb | 28·7 ± 0.1Aa |
| ECL 23141 | 3·5 ± 0.5Bc | 17·5 ± 2.0Ab | 29·5 ± 1.8Aa | |
| ECL 21858 | 3·0 ± 1.8Bc | 10·0 ± 0.3Bb | 24·6 ± 1.9Ba | |
| Depolarized cells (BOX+) | ECL 20440 | 10·2 ± 0.4Ac | 24·5 ± 2.7Bb | 49·0 ± 3.5Ba |
| ECL 23141 | 8·1 ± 1.0Bc | 18·8 ± 1.5Cab | 25·2 ± 0.8Ca | |
| ECL 21858 | 7·6 ± 1.1Bc | 68·1 ± 2.3Ab | 86·9 ± 1.9Aa | |
| Cells without enzymatic activity (cF−) | ECL 20440 | 9·1 ± 0.6Ab | 90·5 ± 2.6Aa | 93·0 ± 1.4Aa |
| ECL 23141 | 5·0 ± 1.6Bb | 91·3 ± 4.7Aa | 96·4 ± 1.4Aa | |
| ECL 21858 | 8·9 ± 1.6Ac | 87·4 ± 1.7Ab | 95·1 ± 2.0Aa | |
| Cells without respiratory activity (CTC−) | ECL 20440 | 5·4 ± 1.1Ab | 58·0 ± 3.2Ca | 61·6 ± 2.3Ca |
| ECL 23141 | 6·0 ± 0.2Ac | 90·7 ± 1.5Ba | 73·8 ± 1.3Bb | |
| ECL 21858 | 7·7 ± 1.7Ab | 97·7 ± 3.7Aa | 99·3 ± 1.4Aa | |
| Cells with compromised efflux pump activity (EB+) | ECL 20440 | 10·5 ± 3.4Ac | 31·2 ± 4.3Bb | 45·6 ± 1.9Ba |
| ECL 23141 | 11·9 ± 0.8Ac | 27·5 ± 3.1Cb | 47·4 ± 1.0Ba | |
| ECL 21858 | 8·6 ± 0.7Bc | 47·6 ± 1.9Ab | 72·2 ± 2.5Aa | |
Different superscript lowercase letters (a–c) in the same row denote significant differences (P < 0·05), based on Kruskal–Wallis test. Different superscript capital letters (A–C) in the same column denote significant differences (P < 0·05) among different strains, for a same treatment and fluorescence stain, based on Kruskal–Wallis test.
Size of subpopulations (average ± standard deviation) of enterotoxigenic Escherichia coli strains (ECL 20440, ECL 23141 and ECL 21858) stained with PI, BOX, cFDA, CTC and EB after exposure to two different concentrations of phenolic‐rich extract from cashew apple by‐product (PEC, 31·25 and 62·50 mg ml−1)
| Cellular structure or function disruption | Enterotoxigenic | Treatments | ||
|---|---|---|---|---|
| Control (without exposure to extract) | PEC (31·25 mg ml−1) | PEC (62·50 mg ml−1) | ||
| Size of subpopulations (%) | ||||
| Permeabilized cells (PI +) | ECL 20440 | 3·8 ± 2.3Ac | 8·7 ± 0.3Ab | 14·92 ± 1.3Aa |
| ECL 23141 | 2·0 ± 0.9Ac | 3·4 ± 1.0Bb | 8·25 ± 1.0Ba | |
| ECL 21858 | 3·2 ± 1.5Ac | 3·9 ± 1.4Bb | 7·91 ± 1.4Ba | |
| Depolarized cells (BOX+) | ECL 20440 | 11·6 ± 0.4Ac | 53·7 ± 1.4Ab | 69·6 ± 3.4Aa |
| ECL 23141 | 6·1 ± 1.0Bb | 57·2 ± 3.4Aa | 59·7 ± 3.5Aa | |
| ECL 21858 | 5·5 ± 1.4Bc | 58·1 ± 4.7Aa | 47·0 ± 2.3Bb | |
| Cells without enzymatic activity (cF−) | ECL 20440 | 3·8 ± 0.2Cb | 19·4 ± 1.9Ba | 65·9 ± 5.1Ba |
| ECL 23141 | 7·4 ± 0.8Ac | 67·0 ± 2.2Ab | 84·4 ± 1.3Aa | |
| ECL 21858 | 4·9 ± 0.2Bc | 64·5 ± 1.8Ab | 80·3 ± 4.6Aa | |
| Cells without respiratory activity (CTC−) | ECL 20440 | 6·5 ± 0.4Ac | 32·3 ± 1.8Cb | 62·3 ± 2.4Ca |
| ECL 23141 | 5·5 ± 0.8Ab | 76·3 ± 4.7Ba | 74·6 ± 3.3Ba | |
| ECL 21858 | 6·9 ± 1.3Ab | 88·1 ± 3.1Aa | 83·1 ± 2.2Aa | |
| Cells with compromised efflux pump activity (EB+) | ECL 20440 | 8·5 ± 1.4Ac | 33·7 ± 2.6Cb | 56·8 ± 2.9Aa |
| ECL 23141 | 8·1 ± 0.2Ab | 51·9 ± 2.2Aa | 53·0 ± 3.5Aa | |
| ECL 21858 | 5·6 ± 0.1Bc | 42·8 ± 3.3Ba | 36·0 ± 5.0Bb | |
Different superscript lowercase letters (a–c) in the same row denote significant differences (P < 0·05), based on Kruskal–Wallis test. Different superscript capital letters (A–C) in the same column denote significant differences (P < 0·05) among different strains, for a same treatment and fluorescence stain, based on Kruskal–Wallis test.